Pre-made Etrolizumab benchmark antibody ( Whole mAb, anti-ITGA4;ITGB7;ITGAE;ITGB7 therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-200

Pre-made Etrolizumab benchmark antibody (Whole mAb, anti-ITGA4;ITGB7;ITGAE;ITGB7 therapeutic antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Etrolizumab (rhuMAb Beta7) is a biopharmaceutical drug candidate being developed for the treatment of ulcerative colitis and Crohn's disease. It is a humanized monoclonal antibody against the β7 subunit of integrins α4β7 and αEβ7. Etrolizumab was developed by Genentech by engineering the FIB504 antibody to include human IgGl-heavy chain and κ-light chain frameworks; it is manufactured in CHO cells.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-200-1mg 1mg 3090 Inquiry Inquiry

Size: 1mg | 10mg | 100mg


Products Name (INN Index) Pre-Made Etrolizumab biosimilar, Whole Mab: Anti-ITGA4;ITGB7;ITGAE;ITGB7 therapeutic antibody
INN Name Etrolizumab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2010
Year Recommended2011
Conditions Approvedna
Conditions ActiveCrohn's disease;Ulcerative colitis
Conditions Discontinuedna
Development Techna